Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 295, Issue 34, Pages 12279-12289Publisher
ELSEVIER
DOI: 10.1074/jbc.REV120.011356
Keywords
nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); AMP-activated protein kinase (AMPK); steatosis; inflammation; liver injury; fibrosis; fatty liver; metabolism; AMP-activated kinase (AMPK); inflammation; liver injury; fibrosis; metabolism
Categories
Funding
- National Institutes of Health [K99HL143277]
Ask authors/readers for more resources
Nonalcoholic fatty liver diseases (NAFLDs), especially nonalcoholic steatohepatitis (NASH), have become a major cause of liver transplant and liver-associated death. However, the pathogenesis of NASH is still unclear. Currently, there is no FDA-approved medication to treat this devastating disease. AMP-activated protein kinase (AMPK) senses energy status and regulates metabolic processes to maintain homeostasis. The activity of AMPK is regulated by the availability of nutrients, such as carbohydrates, lipids, and amino acids. AMPK activity is increased by nutrient deprivation and inhibited by overnutrition, inflammation, and hypersecretion of certain anabolic hormones, such as insulin, during obesity. The repression of hepatic AMPK activity permits the transition from simple steatosis to hepatocellular death; thus, activation might ameliorate multiple aspects of NASH. Here we review the pathogenesis of NAFLD and the impact of AMPK activity state on hepatic steatosis, inflammation, liver injury, and fibrosis during the transition of NAFL to NASH and liver failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available